108 related articles for article (PubMed ID: 20228155)
1. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.
Rajagopalan LE; Davies MS; Kahn LE; Kornmeier CM; Shimada H; Steiner TA; Zweifel BS; Wendling JM; Payne MA; Loeffler RF; Case BL; Norton MB; Parikh MD; Nemirovskiy OV; Mourey RJ; Masferrer JL; Misko TP; Kolodziej SA
J Pharmacol Exp Ther; 2010 Jun; 333(3):707-16. PubMed ID: 20228155
[TBL] [Abstract][Full Text] [Related]
2. Activation of Rho kinase isoforms in lung endothelial cells during inflammation.
Mong PY; Wang Q
J Immunol; 2009 Feb; 182(4):2385-94. PubMed ID: 19201893
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
4. The role of the cytoskeleton in cellular adhesion molecule expression in tumor necrosis factor-stimulated endothelial cells.
VandenBerg E; Reid MD; Edwards JD; Davis HW
J Cell Biochem; 2004 Apr; 91(5):926-37. PubMed ID: 15034928
[TBL] [Abstract][Full Text] [Related]
5. A role for Rho-kinase in Ca-independent contractions induced by phorbol-12,13-dibutyrate.
Baek I; Jeon SB; Kim J; Seok YM; Song MJ; Chae SC; Jun JE; Park WH; Kim IK
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):256-61. PubMed ID: 18986333
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
7. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets.
Thienel U; Loike J; Yellin MJ
Cell Immunol; 1999 Dec; 198(2):87-95. PubMed ID: 10648122
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease.
Stinghen AE; Gonçalves SM; Martines EG; Nakao LS; Riella MC; Aita CA; Pecoits-Filho R
Nephron Clin Pract; 2009; 111(2):c117-26. PubMed ID: 19147993
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.
Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K
Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948
[TBL] [Abstract][Full Text] [Related]
10. A chromone analog inhibits TNF-alpha induced expression of cell adhesion molecules on human endothelial cells via blocking NF-kappaB activation.
Kumar S; Singh BK; Pandey AK; Kumar A; Sharma SK; Raj HG; Prasad AK; Van der Eycken E; Parmar VS; Ghosh B
Bioorg Med Chem; 2007 Apr; 15(8):2952-62. PubMed ID: 17321745
[TBL] [Abstract][Full Text] [Related]
11. Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells.
Gutjahr MC; Rossy J; Niggli V
Exp Cell Res; 2005 Aug; 308(2):422-38. PubMed ID: 15950966
[TBL] [Abstract][Full Text] [Related]
12. Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors.
Hopkins AM; Pineda AA; Winfree LM; Brown GT; Laukoetter MG; Nusrat A
Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G806-17. PubMed ID: 17138966
[TBL] [Abstract][Full Text] [Related]
13. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
14. Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition.
Schlüter T; Steinbach AC; Steffen A; Rettig R; Grisk O
Cardiovasc Res; 2008 Nov; 80(2):271-9. PubMed ID: 18596059
[TBL] [Abstract][Full Text] [Related]
15. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
16. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
17. AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression.
Kunsch C; Luchoomun J; Chen XL; Dodd GL; Karu KS; Meng CQ; Marino EM; Olliff LK; Piper JD; Qiu FH; Sikorski JA; Somers PK; Suen KL; Thomas S; Whalen AM; Wasserman MA; Sundell CL
J Pharmacol Exp Ther; 2005 May; 313(2):492-501. PubMed ID: 15701708
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865).
Oh KS; Oh BK; Park CH; Seo HW; Kang NS; Lee JH; Lee JS; Ho Lee B
Eur J Pharmacol; 2013 Feb; 702(1-3):218-26. PubMed ID: 23376156
[TBL] [Abstract][Full Text] [Related]
19. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation.
Saito H; Minamiya Y; Saito S; Ogawa J
J Leukoc Biol; 2002 Oct; 72(4):829-36. PubMed ID: 12377953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
